Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome

Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome

This study investigated the effects of long-term treatment with rifaximin and the probiotic VSL#3 on uro-genital and gastrointestinal symptoms in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) plus diarrhoea-predominant irritable bowel syndrome (D-IBS) compared with patient...

Full description

Bibliographic Details
Main Authors: Enzo Vicari, Michele Salemi, Giuseppe Sidoti, Mariano Malaguarnera, Roberto Castiglione
Format: Article
Language:English
Published: MDPI AG 2017-11-01
Series:Nutrients
Subjects:
chronic pelvic pain syndrome
irritable bowel syndrome
irritable bowel syndrome-severity scoring system
rifaximin
probiotic VSL#3
Online Access:https://www.mdpi.com/2072-6643/9/11/1208

Internet

https://www.mdpi.com/2072-6643/9/11/1208

Similar Items